Superficial bladder cancer: part 2. Management.

References

• Pietrow PK, Smith JA Jr. Laser treatment for invasive and noninvasive carcinoma of the bladder. J. Endourol.15(4), 415–418 (2001).
   PubMed Web of Science ®Google Scholar
• Syed HA, Biyani CS, Bryan N et al. Holmium:YAG laser treatment of recurrent superficial bladder carcinoma: initial clinical experience. J. Endourol.15(6), 625–627 (2001).
   PubMed Web of Science ®Google Scholar
• Beisland HO, Seland P. A prospective randomized study on neodymium–YAG laser irradiation versus TUR in the treatment of urinary bladder cancer. Scand. J. Urol. Nephrol.20(3), 209–212 (1986).
   PubMed Web of Science ®Google Scholar
• Zurkirchen MA, Sulser T, Gaspert A et al. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol. Int.72(2), 99–102 (2004).
   PubMed Web of Science ®Google Scholar
• Schips L, Augustin H, Ziguener RE et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology59(2), 220–223 (2002).
   PubMed Web of Science ®Google Scholar
• Duttal SC, Smith JA Jr, Shappell SB et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol.166(2), 490–493 (2001).
   PubMed Web of Science ®Google Scholar
• Jakse G, Algaba F, Malmstrom PU et al. A second-look TUR in T1 transitional cell carcinoma: why? Eur. Urol.45(5), 539–546 (2004).
   PubMed Web of Science ®Google Scholar
• Badalament RA, Farah RN. Treatment of superficial bladder cancer with intravesical chemotherapy. Semin. Surg. Oncol.13(5), 335–341 (1997).
   PubMedGoogle Scholar
• Andius P, Fehrling M, Holmang S. Intravesical bacillus Calmette–Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. Br. J. Urol. Int.96(9), 1290–1293 (2005).
   Google Scholar
• Bouffioux C, Denis L, Oosterlinck W et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J. Urol.148(2 Pt 1), 297–301 (1992).
   PubMed Web of Science ®Google Scholar
• Rajala P, Kaasinen E, Raitanen M et al. Perioperative single dose instillation of epirubicin or interferon-α after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study – FinnBladder III long-term results. J. Urol.168(3), 981–985 (2002).
   PubMed Web of Science ®Google Scholar
• Solsona E, Iborra I, Ricos JV et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J. Urol.161(4), 1120–1123 (1999).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171(6 Pt 1), 2186–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Tolley DA, Parmar MK, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J. Urol.155(4), 1233–1238 (1996).
   PubMed Web of Science ®Google Scholar
• Ali-el-Dein B, Nabeeh A, el-Baz M et al. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br. J. Urol.79(5), 731–735 (1997).
   PubMedGoogle Scholar
• Lamm DL, Riggs DR, Traynelis CL et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol.153, 1444–1450 (1995).
   PubMed Web of Science ®Google Scholar
• Bouffioux C, Kurth KH, Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J. Urol.153(3 Pt 2), 934–941 (1995).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Geschwind JF, Witherspoon B et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J. Clin. Epidemiol.53(7), 676–680 (2000).
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Solsona E, Akaza H et al. Low-grade Ta (non-invasive) urothelial carcinoma of the bladder. Br. J. Urol.66(Suppl. 6A), 75–89 (2005).
   Google Scholar
• Jones HC, Swinney J. Thiotepa in the treatment of tumors of the bladder. Lancet2, 615–618 (1961).
   PubMed Web of Science ®Google Scholar
• Prout GR Jr, Koontz WW Jr, Coombs LJ et al. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J. Urol.130, 677–680 (1983).
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party on Urologic Cancer, Subgroup on Superficial Bladder Cancer. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Br. J. Urol.73, 632–638 (1994).
   PubMedGoogle Scholar
• Herr HW, Lamm DL, Denis L. Management of superficial bladder cancer. In: Principles and Practice of Genitourinary Oncology. Raghavan D, Scher HI, Leibel SA, Lange PH (Eds). Lippincott-Raven, PA, USA Chapter 273 (1997).
   Google Scholar
• Soloway MS, Ford KS. Thiotepa-induced myelosuppression: review of 670 bladder instillations. J. Urol.130, 889–891 (1983).
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial. J. Natl Cancer Inst.93, 597–604 (2001).
   PubMed Web of Science ®Google Scholar
• Heney NM. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa. Urology26, 27–29 (1985).
   PubMed Web of Science ®Google Scholar
• Solsona E, Iborra I, Ricos JV et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J. Urol.161, 1120–1123 (1999).
   PubMed Web of Science ®Google Scholar
• Koontz WW Jr, Heney NM, Soloway MS et al. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group. Urology26, 30–31 (1985).
   PubMed Web of Science ®Google Scholar
• Soloway MS. Diagnosis and management of superficial bladder cancer. Semin. Surg. Oncol.5, 247–254 (1989).
   PubMedGoogle Scholar
• Crawford ED, McKenzie D, Mansson W et al. Adverse reactions to the intravesical administration of doxorubicin hydrochloride: a report of six cases. J. Urol.136, 668 (1986).
   PubMed Web of Science ®Google Scholar
• Zincke H, Utz DC, Taylor WF et al. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J. Urol.129, 505–509 (1983).
   PubMed Web of Science ®Google Scholar
• Llopis B, Gallego J, Mompo JA et al. Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors. Eur. Urol.11, 73–78 (1985).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Riggs DR, Traynelis CL et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol.153, 1444–1450 (1995).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Geschwind JF, Witherspoon B et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J. Clin. Epidemiol.53(7), 676–680 (2000).
   PubMed Web of Science ®Google Scholar
• Huland H, Kloppel G, Feddersen I et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J. Urol.144(1), 68–71 (1990).
   PubMed Web of Science ®Google Scholar
• Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol.156, 1934–1940 (1996).
   PubMed Web of Science ®Google Scholar
• Malmstrom PU. Intravesical therapy of superficial bladder cancer. Crit. Rev. Oncol. Hematol.47(2), 109–126 (2003).
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette and Guerin in the treatment of superficial bladder tumors. J. Urol.116, 18 (1976).
   Google Scholar
• Ratliff TL, Kavoussi LR, Catalona WJ. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J. Urol.139, 410–414 (1988).
   PubMed Web of Science ®Google Scholar
• Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol.137, 155–158 (1987).
   PubMed Web of Science ®Google Scholar
• Ratliff TL, Ritchey JK, Yuan JJ et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol.150, 1018–1023 (1993).
   PubMed Web of Science ®Google Scholar
• Garden RJ, Liu BC, Redwood SM et al. Bacillus Calmette–Guerin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction. J. Urol.148, 900–905 (1992).
   PubMed Web of Science ®Google Scholar
• Bohle A, Brandau S. Immune mechanisms in bacillus Calmette–Guerin immunotherapy for superficial bladder cancer. J. Urol.170(3), 964–969 (2003).
   PubMed Web of Science ®Google Scholar
• Shelley MD, Court JB, Kynaston H et al. Intravesical bacillus Calmette–Guerin in Ta and T1 bladder cancer. Cochrane Database Syst. Res.4, CD001986 (2000).
   Google Scholar
• Lamm DL, van der Meijden PM, Morales A et al. Incidence and treatment of complications of bacillus Calmette–Guerin intravesical therapy in superficial bladder cancer. J. Urol.147(3), 596–600 (1992).
   PubMed Web of Science ®Google Scholar
• Durek C, Jurczok A, Werner H et al. Optimal treatment of systemic bacillus Calmette–Guerin infection: investigations in an animal model. J. Urol.168(2), 826–831 (2002).
   PubMed Web of Science ®Google Scholar
• Lamm DL. Bacillus Calmette–Guerin immunotherapy for bladder cancer. J. Urol.134, 40–47 (1985).
   PubMed Web of Science ®Google Scholar
• Pagano F, Bassi P, Milani C. et al. A low dose bacillus Calmette–Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol.146, 32–35 (1991).
   PubMed Web of Science ®Google Scholar
• Krege S, Giani G, Meyer R et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette–Guerin. Participating clinics. J. Urol.156(3), 962–966 (1996).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette–Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med.325(17), 1205–1209 (1991).
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr et al. Bacillus Calmette–Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol.143(3), 502–506 (1990).
   PubMed Web of Science ®Google Scholar
• Cheng CW, Chan SF, Chan LW et al. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette–Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int. J. Urol.12(5), 449–455 (2005).
   PubMed Web of Science ®Google Scholar
• Melekos MD, Zarakovitis I, Dandinis K et al. BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes. Int. Urol. Nephrol.28(4), 499–509 (1996).
   PubMedGoogle Scholar
• Rintala E, Jauhiainen K, Alfthan O et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette–Guerin) in superficial bladder cancer. Eur. Urol.20(1), 19–25 (1991).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Crawford ED, Blumenstein B et al. Randomized comparison of bacillus Calmette–Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol. Oncol.1, 119 (1995).
   PubMedGoogle Scholar
• Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette–Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol.169(1), 90–95 (2003).
   PubMed Web of Science ®Google Scholar
• Herr HW, Wartinger DD, Fair WR et al. Bacillus Calmette–Guerin therapy for superficial bladder cancer: a 10-year followup. J. Urol.147, 1020–1023 (1992).
   PubMed Web of Science ®Google Scholar
• Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette–Guerin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol.6, 1450–1455 (1988).
   PubMed Web of Science ®Google Scholar
• Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette–Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol.13, 1404–1408 (1995).
   PubMed Web of Science ®Google Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol.163, 73–78 (2000).
   PubMed Web of Science ®Google Scholar
• Melekos MD, Chionis H, Pantazakos A et al. Intravesical bacillus Calmette–Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J. Urol.149, 744–748 (1993).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol.168(5), 1964–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Bohle A, Bock PR. Intravesical bacille Calmette–Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology63(4), 682–686 (2004).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomized controlled trial. Lancet Oncol.7, 43–51 (2006).
   PubMed Web of Science ®Google Scholar
• Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. North Am.19, 573–580 (1992).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Witjes JA et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology66(6 Suppl. 1), 90–107 (2005).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden A, Witjes JA et al. Bacillus Calmette–Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol.174, 86–91 (2005).
   PubMed Web of Science ®Google Scholar
• Cookson MS, Herr HW, Zhang ZF et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol.158, 62–67 (1997).
   PubMed Web of Science ®Google Scholar
• Herr HW. Extravesical tumor relapse in patients with superficial bladder tumors. J. Clin. Oncol.16, 1099–1102 (1998).
   PubMed Web of Science ®Google Scholar
• Nadler RB, Catalona WJ, Hudson MA et al. Durability of the tumor-free response for intravesical bacillus Calmette–Guerin therapy. J. Urol.152, 367–373 (1994).
   PubMed Web of Science ®Google Scholar
• Kelley DR, Ratliff TL, Catalona WJ et al. Intravesical bacillus Calmette–Guerin therapy for superficial bladder cancer: effect of bacillus Calmette–Guerin viability on treatment results. J. Urol.134, 48–53 (1985).
   PubMed Web of Science ®Google Scholar
• Haaff EO, Dresner SM, Ratliff TL et al. Two courses of intravesical bacillus Calmette–Guerin for transitional cell carcinoma of the bladder. J. Urol.136, 820–824 (1986).
   PubMed Web of Science ®Google Scholar
• Sarosdy MF, Lamm DL. Long-term results of intravesical bacillus Calmette–Guerin therapy for superficial bladder cancer. J. Urol.142, 719–722 (1989).
   PubMed Web of Science ®Google Scholar
• Coplen DE, Marcus MD, Myers JA et al. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette–Guerin: analysis of possible predictors of response free of tumor. J. Urol.144, 652–657 (1990).
   PubMed Web of Science ®Google Scholar
• Jakse G, Hall R, Bono A et al; for the EROTC GU Group. Intravesical BCG in patients with carcinoma-in-situ of the urinary bladder: long term results of the EROTC GU Group Phase II protocol 30861. Eur. Urol.40, 144–150 (2001).
   PubMed Web of Science ®Google Scholar
• Badalament RA, Herr HW, Wong GY et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette–Guerin therapy of superficial bladder cancer. J. Clin. Oncol.5, 441–449 (1987).
   PubMed Web of Science ®Google Scholar
• Hudson MA, Ratliff TL, Gillen DP et al. Single course versus maintenance bacillus Calmette–Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J. Urol.138, 295–298 (1987).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette–Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol.163(4), 1124–1129 (2000).
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E et al. Has a 3-fold decreased dose of bacillus Calmette–Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol.174(4 Pt 1), 1242–1247 (2005).
   PubMed Web of Science ®Google Scholar
• Pagano F, Bassi P, Milani C et al. A low dose bacillus Calmette–Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol.146(1), 32–35 (1991).
   PubMed Web of Science ®Google Scholar
• Losa A, Hurle R, Lembo A. Low dose bacillus Calmette–Guerin for carcinoma in situ of the bladder: long-term results. J. Urol.163, 68–71 (2000).
   PubMed Web of Science ®Google Scholar
• Mack D, Frick J. Five-year results of a Phase II study with low-dose bacilli Calmette–Guerin therapy in high-risk superficial bladder cancer. Urology45, 958–961 (1995).
   PubMed Web of Science ®Google Scholar
• Torti FM, Shortliffe LD, Williams RD et al. α-Interferon in superficial bladder cancer: a Northern California Oncology Group Study. J. Clin. Oncol.6, 476–483 (1988).
   PubMed Web of Science ®Google Scholar
• Glashan RW. A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. J. Urol.144, 658–661 (1990).
   PubMed Web of Science ®Google Scholar
• Belldegrun AS, Franklin JR, O’Donnell MA et al. Superficial bladder cancer: the role of interferon-α. J. Urol.159(6), 1793–1801 (1998).
   PubMed Web of Science ®Google Scholar
• Portillo J, Martin B, Hernandez R et al. Results at 43 months’ follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon α-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology49(2), 187–190 (1997).
   PubMed Web of Science ®Google Scholar
• Kalble T, Beer M, Mendoza E et al. BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A33(2), 133–137 (1994).
   PubMedGoogle Scholar
• Ferrari P, Castagnetti G, Pollastri CA et al. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-α 2b versus interferon-α 2b with epirubicin. Anticancer Drugs3(Suppl. 1), 25–27 (1992).
   PubMedGoogle Scholar
• Riggs DR, Tarry WF, DeHaven JI et al. Immunotherapy of murine transitional cell carcinoma of the bladder using α and γ interferon in combination with other forms of immunotherapy. J. Urol.147, 212–214 (1992).
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette–Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette–Guerin alone previously failed. J. Urol.166, 1300–1305 (2001).
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Lilli K, Leopold C et al. Interim results from a national multicenter Phase II trial of combination bacillus Calmette–Guerin plus interferon α-2b for superficial bladder cancer. J. Urol.172(3), 888–893 (2004).
   PubMed Web of Science ®Google Scholar
• Greenberg RE, Bahnson RR, Wood D et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology49(3), 471–475 (1997).
   PubMed Web of Science ®Google Scholar
• Steinberg G, Bahnson R, Brosman S et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette–Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J. Urol.163(3), 761–767 (2000).
   PubMed Web of Science ®Google Scholar
• Newling DW, Hetherington J, Sundaram SK et al. The use of valrubicin for the chemoresection of superficial bladder cancer – a marker lesion study. Eur. Urol.39(6), 643–647 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J. Urol.174(1), 14–20 (2005).
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Sheinfeld J et al. Phase I trial of intravesical gemcitabine in bacillus Calmette–Guerin-refractory transitional-cell carcinoma of the bladder. J. Clin. Oncol.20(15), 3193–3198 (2002).
   PubMed Web of Science ®Google Scholar
• Laufer M, Ramalingam S, Schoenberg MP et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a Phase I and pharmacokinetic study. J. Clin. Oncol.21(4), 697–703 (2003).
   PubMed Web of Science ®Google Scholar
• Witjes JA, van der Heijden AG, Vriesema JL et al. Intravesical gemcitabine a Phase 1 and pharmacokinetic study. Eur. Urol.45, 182–186 (2004).
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Gacci M et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology66(4), 726–731 (2005).
   PubMed Web of Science ®Google Scholar
• Sarosdy MF, Lamm DL, Williams RD et al. Phase 1 trial of oral bropirimine in superficial bladder cancer. J. Urol.147, 31–33 (1992).
   PubMed Web of Science ®Google Scholar
• Sarosdy MF, Lowe BA, Schellhammer PF et al. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a Phase II trial. Urology48, 21–27 (1996).
   PubMed Web of Science ®Google Scholar
• Sarosdy MF, Pisters LL, Carroll PR et al. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology48, 28–32 (1996).
   PubMed Web of Science ®Google Scholar
• Sardosy MF, Tangen CM, Weiss GR et al. A Phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette–Guerin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. Urol. Oncol.23(6), 386–389 (2005).
   PubMed Web of Science ®Google Scholar
• Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J. Urol.115, 150–151 (1976).
   PubMed Web of Science ®Google Scholar
• Nseyo UO, Shumaker B, Klein EA et al. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. J. Urol.160, 39–44 (1998).
   PubMed Web of Science ®Google Scholar
• Nseyo UO. Photodynamic therapy in the management of bladder cancer. J. Clin. Laser Med. Surg.14, 271–280 (1996).
   PubMedGoogle Scholar
• Nseyo UO. Photodynamic therapy. Urol. Clin. North Am.19, 591–599 (1992).
   PubMed Web of Science ®Google Scholar
• Manyak MJ, Ogan K. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J. Endourol.17(8), 633–639 (2003).
   PubMed Web of Science ®Google Scholar
• Yalcin O, Karatas F, Erulas FA et al. The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. Br. J. Urol. Int.93(6) 863–866 (2004).
   Google Scholar
• Lamm DL, Riggs DR, Shriver JS et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J. Urol.151, 21–26 (1994).
   PubMed Web of Science ®Google Scholar
• Perrotte P, Wood M, Slaton JW et al. Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology56, 155–159 (2000).
   PubMed Web of Science ®Google Scholar
• Shimizu H, Akasaka S, Suzuki S et al. Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector. Urology57(3), 579–584 (2001).
   PubMed Web of Science ®Google Scholar
• El-Zawahry A, Lu P, White SJ et al. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of CFLIP and Bcl-XL. Cancer Gene Ther.13, 281–289 (2006).
   PubMed Web of Science ®Google Scholar
• Melquist JJ, Kacka M, Yingming L et al. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model. Urol. Oncol.24, 362–371 (2006).
   PubMed Web of Science ®Google Scholar
• Stockle M, Alken P, Engelmann U et al. Radical cystectomy – often too late? Eur. Urol.13, 361–367 (1987).
   PubMed Web of Science ®Google Scholar
• Hautmann RE, Paiss T. Does the option of the ileal neobladder stimulate patient and physician decision towards earlier cystectomy? J. Urol.159, 1845–1850 (1998).
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19, 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Ghoneim MA, El-Mekresh MM, El-Baz MA et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J. Urol.158, 393–399 (1997).
   PubMed Web of Science ®Google Scholar
• Amling CL, Trasher JB, Frazier HA et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J. Urol.151, 31–35 (1994).
   PubMed Web of Science ®Google Scholar
• Freeman JA, Esrig D, Stein JP et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer76, 833–839 (1995).
   PubMed Web of Science ®Google Scholar
• Pasin E, Buscarini M, Stein JP. Complications of radical cystectomy. In: Complications of Urologic Surgery and Practice: Diagnosis, Prevention and Management. Loughlin KR (Ed.). Informa Health Care, London, UK (In Press).
   Google Scholar
• Kim HL, Steinberg GD. The current status of bladder preservation in the management of muscle invasive bladder cancer J. Urol.164, 627–632 (2000).
   PubMed Web of Science ®Google Scholar